River Street Advisors LLC Grows Position in Zoetis Inc. $ZTS

River Street Advisors LLC raised its stake in shares of Zoetis Inc. (NYSE:ZTS) by 33.3% in the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 3,614 shares of the company’s stock after purchasing an additional 903 shares during the period. River Street Advisors LLC’s holdings in Zoetis were worth $564,000 as of its most recent filing with the Securities & Exchange Commission.

Other large investors have also recently made changes to their positions in the company. Lindbrook Capital LLC raised its stake in Zoetis by 1.8% during the first quarter. Lindbrook Capital LLC now owns 3,715 shares of the company’s stock valued at $612,000 after purchasing an additional 65 shares in the last quarter. Scott & Selber Inc. lifted its holdings in shares of Zoetis by 0.6% in the 2nd quarter. Scott & Selber Inc. now owns 11,652 shares of the company’s stock valued at $1,817,000 after acquiring an additional 67 shares during the last quarter. Secure Asset Management LLC raised its position in Zoetis by 2.9% during the second quarter. Secure Asset Management LLC now owns 2,448 shares of the company’s stock valued at $382,000 after purchasing an additional 68 shares during the period. Quotient Wealth Partners LLC boosted its holdings in shares of Zoetis by 2.3% in the 1st quarter. Quotient Wealth Partners LLC now owns 3,167 shares of the company’s stock worth $521,000 after purchasing an additional 72 shares during the period. Finally, Broadway Wealth Solutions Inc. raised its holdings in Zoetis by 4.4% during the 1st quarter. Broadway Wealth Solutions Inc. now owns 1,746 shares of the company’s stock valued at $287,000 after buying an additional 73 shares during the period. 92.80% of the stock is owned by institutional investors.

Zoetis Stock Performance

ZTS opened at $146.46 on Friday. The company has a market cap of $64.91 billion, a P/E ratio of 25.21, a price-to-earnings-growth ratio of 2.36 and a beta of 0.90. The company has a quick ratio of 1.04, a current ratio of 1.76 and a debt-to-equity ratio of 1.05. The firm’s 50-day moving average price is $149.89 and its 200-day moving average price is $155.26. Zoetis Inc. has a 52-week low of $139.34 and a 52-week high of $196.55.

Zoetis (NYSE:ZTS) last posted its quarterly earnings results on Tuesday, August 5th. The company reported $1.76 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.62 by $0.14. Zoetis had a net margin of 27.83% and a return on equity of 56.90%. The company had revenue of $2.46 billion during the quarter, compared to analyst estimates of $2.41 billion. During the same period last year, the firm posted $1.56 EPS. Zoetis’s revenue for the quarter was up 4.2% compared to the same quarter last year. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. As a group, equities analysts anticipate that Zoetis Inc. will post 6.07 EPS for the current fiscal year.

Analysts Set New Price Targets

Several equities research analysts have recently issued reports on the stock. Stifel Nicolaus lowered shares of Zoetis from a “buy” rating to a “hold” rating and lowered their target price for the stock from $165.00 to $160.00 in a report on Wednesday, June 18th. Leerink Partnrs cut Zoetis from a “strong-buy” rating to a “hold” rating in a report on Thursday, July 17th. Piper Sandler lifted their target price on Zoetis from $210.00 to $215.00 and gave the stock an “overweight” rating in a research report on Monday, August 11th. Argus reaffirmed a “buy” rating and issued a $190.00 price target on shares of Zoetis in a research note on Tuesday, September 9th. Finally, Leerink Partners downgraded shares of Zoetis from an “outperform” rating to a “market perform” rating and dropped their target price for the stock from $180.00 to $155.00 in a research note on Thursday, July 17th. Five equities research analysts have rated the stock with a Buy rating and four have given a Hold rating to the company. Based on data from MarketBeat.com, Zoetis has a consensus rating of “Moderate Buy” and a consensus target price of $200.88.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.